Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)

NCT ID: NCT02160782

Last Updated: 2021-07-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-28
• Study Completion Date: 2020-05-28

Brief Summary

This is a long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period in children with Alagille Syndrome (ALGS) designed to evaluate the safety and efficacy of LUM001 (Also known as maralixibat or MRX).

Detailed Description

The study is divided into 6 parts: a 6-week open-label, dose escalation period, a 12-week open-label stable dosing period, a 4-week randomized, double-blind, placebo-controlled drug withdrawal period, a 26-week long-term stable dosing period, and an a 52-week optional follow-up treatment period, and a long-term optional follow-up treatment period for eligible participants who choose to stay on treatment with LUM001.

Conditions

Alagille Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

LUM001 (Maralixibat)

LUM001, also known as Maralixibat (MRX) will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid [sBA] level and ItchRO[Obs] score) and safety assessment.

Note: 400 mcg/kg maralixibat chloride is equivalent to 380 mcg/kg free maralixibat.

Group Type: EXPERIMENTAL

LUM001 (Maralixibat)

Intervention Type: DRUG

LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.

Placebo

Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo will be administered orally once daily during randomized withdrawal period

Interventions

LUM001 (Maralixibat)

LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.

Intervention Type: DRUG

Placebo

Placebo will be administered orally once daily during randomized withdrawal period

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or female between the ages of 12 months and 18 years inclusive.
• Diagnosis of ALGS.
• Evidence of cholestasis (one or more of the following):

1. Total serum bile acid > 3x ULN for age.

2. Conjugated bilirubin > 1 mg/dL.

3. Fat soluble vitamin deficiency otherwise unexplainable.

4. GGT > 3x ULN for age.

5. Intractable pruritus explainable only by liver disease.

• Females of childbearing potential must have a negative serum pregnancy test during Screening.
• Males and females of child-bearing potential who are sexually active, or are not currently sexually active during the study, but become sexually active during the period of the study and 30 days following the last dose of study drug, must agree and use acceptable contraception during the trial.
• Participant is expected to have a consistent caregiver(s) for the duration of the study.
• Informed consent and assent (per IRB/IEC) as appropriate.
• Access to phone for scheduled calls from study site.
• Caregivers (and age-appropriate participants) must be willing and able to use an eDiary device during the study.
• Caregivers (and age-appropriate participants) must digitally accept the licensing agreement in the eDiary software.
• Caregivers (and age-appropriate participants) must complete at least 10 eDiary reports (morning or evening) during each of two consecutive weeks of the screening period (maximum possible reports = 14 per week).
• Average daily score >2 on the Itch Reported Outcome (ItchRO™) questionnaire (maximum possible daily score of 4) for two consecutive weeks in the screening period, prior to dosing. A daily score is the higher of the scores for the morning and evening ItchRO. The average daily score is the sum of all daily scores divided by the number of days the ItchRO was completed.

• Completed the protocol through the Week 48 visit with no safety concerns. Participants who were discontinued due to safety reasons can be rechallenged if blood tests are back to relatively normal values for this patient population and participant does not meet any of the protocol's stopping rules. The decision will be made by the investigator in consultation with the sponsor medical monitor.
• Participants who have undergone a surgical disruption of the enterohepatic circulation will not be eligible to enter into the follow up treatment period.
• Participants who were discontinued for other reasons will be considered for the 52-week optional follow-up treatment period on an individual basis. The decision will be made by the investigator in consultation with the sponsor medical monitor.

• The Participant has either: completed the protocol through the Week 48 visit with no major safety concerns OR discontinued due to safety reasons judged unrelated to the study drug, and laboratory results have returned to levels acceptable for this patient population or individual and participant does not meet any of the protocol's stopping rules at the time of entry into the follow-up period. The decision will be made by the investigator in consultation with the sponsor medical monitor. [Participants who were discontinued for other reasons will be considered on an individual basis.]
• Females of childbearing potential must have a negative urine or serum pregnancy test (beta- human chorionic gonadotropin [β-hCG]) at the time of entry into the long-term optional follow-up treatment period.
• Males and females of child-bearing potential who are sexually active, or are not currently sexually active during the study, but become sexually active during the period of the study and 30 days following the last dose of study drug, must agree and use acceptable contraception during the trial.
• Informed consent and assent (per IRB/EC) as appropriate.
• Access to phone for scheduled calls from study site.
• Caregivers (and age-appropriate participants) must be willing and able to use an eDiary device during the study.

Exclusion Criteria

• Chronic diarrhea requiring ongoing intravenous fluid or nutritional intervention.
• Surgical interruption of the enterohepatic circulation.
• Previous liver transplant
• Decompensated cirrhosis (ALT >15 x ULN, INR >1.5 [unresponsive to vitamin K therapy], albumin <3.0 g/dL, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy).
• History or presence of other concomitant liver disease.
• History or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease).
• History or presence of gallstones or kidney stones.
• Known diagnosis of human immunodeficiency virus (HIV) infection.
• Cancers, except for in situ carcinoma, or cancers treated at least 5 years prior to Screening with no evidence of recurrence.
• Recent medical history or current status that suggests that the participant may be unable to complete the study.
• Any female who is pregnant or lactating or who is planning to become pregnant during the study period.
• Known history of alcohol or substance abuse.
• Administration of bile acid or lipid binding resins within 28 days prior to screening and throughout the trial.
• Known hypersensitivity to LUM001 or any of its components.
• Receipt of investigational drug, biologic, or medical device within 28 days prior to screening, or 5 half-lives of the study agent, whichever is longer.
• History of non-adherence to medical regimens, unreliability, mental instability or incompetence that could compromise the validity of informed consent or lead to nonadherence with the study protocol based upon investigator judgment.
• Any other conditions or abnormalities which, in the opinion of the investigator or sponsor medical monitor, may compromise the safety of the participant, or interfere with the participant participating in or completing the study.
• Participants weighing over 50 kg at screening.

• Minimum Eligible Age: 12 Months
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mirum Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Mirum

Locations

Children's Hospital Westmead

Westmead, New South Wales, Australia

The Royal Children's Hospital Melbourne

Parkville, Victoria, Australia

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Hopital Femme Mere Enfant De Lyon

Bron, , France

Hopital Necker-Enfants Malades

Paris, , France

Hopital Kremlin Bicetre

Paris, , France

The Children's Memorial Health Institute

Warsaw, , Poland

Hospital Universitario La Paz- Hospital Materno Infantil

Madrid, , Spain

Paediatric Liver Center, Kings College Hospital

London, , United Kingdom

Countries

Australia; Belgium; France; Poland; Spain; United Kingdom

References

Kamath BM, Goldstein A, Howard R, Garner W, Vig P, Marden JR, Billmyer E, Anderson A, Kirson N, Jacquemin E, Gonzales E. Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life. J Pediatr. 2023 Jan;252:68-75.e5. doi: 10.1016/j.jpeds.2022.09.001. Epub 2022 Sep 10.

Reference Type: DERIVED

PMID: 36096175 (View on PubMed)

Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D, Lacaille F, Lachaux A, Sturm E, Setchell KDR, Kennedy C, Dorenbaum A, Steinmetz J, Desai NK, Wardle AJ, Garner W, Vig P, Jaecklin T, Sokal EM, Jacquemin E. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021 Oct 30;398(10311):1581-1592. doi: 10.1016/S0140-6736(21)01256-3. Epub 2021 Oct 28.

Reference Type: DERIVED

PMID: 34755627 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2013-005373-43

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

LUM001-304

Identifier Type: -

Identifier Source: org_study_id